Table 1.
Parameter estimation
| Pharmacodynamic parameters | Estimate (95% CI) | 991 Bootstrapped median (95% CI) |
|---|---|---|
| Emax-placebo,% | 58.1 (54.2~62.0) | 57.5 (50.5~62.0) |
| ET50-placebo,wk | 3.83 (3.24~4.42) | 3.73 (1.14~4.46) |
| Emax-drug,% | 16.4 (13.4~19.5) | 15.8 (0.65~21.7) |
| ET50-drug,week | 5.36 (3.55~7.17) | 5.45 (3.57~9.17) |
| θ Status on Emax,% | 18.4 (7.94~28.9) | 20.30(7.71~45.15) |
| θ Centre on Emax,% | 10.2 (4.26~16.1) | 11.40(3.84~36.93) |
| Variability parameters | ||
| η (Emax-placebo),% | 14.2 (11.4~17.0) | 14.3 (11.4~17.3) |
| η (ET50-placebo),% | 1.68 (1.31~2.05) | 1.73 (1.30~3.01) |
| η (ET50-drug),% | 2.56 (1.79~3.33) | 2.45 (0.00~3.57) |
| ε ,% | 2.54 (2.33~3.75) | 2.53 (2.34~2.76) |
Abbreviations: Emax-drug, maximal pure effect of drug; Emax-placebo, maximal effect of placebo; ET50-drug, time to achieve 50% of Emax-drug; ET50-placebo, time to achieve 50% of Emax-placebo; η, variability of pharmacodynamic parameter; ε, residual error.